pokatok prep

New sports festival reveals plans to take over downtown Houston next spring

A new sports festival is headed to Houston next year. Rendering courtesy of Pokatok

A Houston team announced their plans to bring the “world’s fair for sports” to downtown Houston in April 2024.

Pokatok, the four-day festival, will feature a sports tech expo, a film festival, speakers and panels, live music, pitch competitions, and more. The venue will be George R. Brown Convention Center, Discovery Green, and various nearby hotels, according to the release.

Gow Companies, founded by Lawson Gow (who is the son of David Gow, InnovationMap's parent company's CEO), announced that the team has secured support from Houston First, the Greater Houston Partnership, and the Harris County Houston Sports Authority to put on the event, which is slated to take place April 4-7, 2024. The company also owns Houston Exponential and a sports accelerator called Pokatok Labs.

“Pokatok will not only be the largest gathering of the entire sports tech ecosystem, it will also be a true fan festival for sports enthusiasts,” says Gow in the news release. “Everyone speaks the language of sport, it’s an incredibly powerful unifier of our society, and this festival will bring together people from around the world to experience hundreds of events revolving around the new and the next in sport.”

The festival will take place in April 2024 in downtown. Rendering courtesy of Pokatok

The festival will feature two tracks — one focused on sports innovation and the other surrounding a fan experience. Pokatok X will include an expo and showcase focused on sports innovation, bringing together startups, investors, accelerators, athletes, and industry experts to dive into sports tech.

The Pokatok Fan Festival's track will include product releases, demos for sports technology, sporting events, competitions, tournaments, and more.

Houston is no stranger to hosting major sport events, Harris County - Houston Sports Authority CEO Janis Burke points out in the news release, including the 2023 NCAA Men’s Final Four and the upcoming 2024 College Football National Championship, the 2024 Cricket World Cup, and the 2026 FIFA World Cup.

"Houston is known as one of the best sports destinations in the world," Burke continues. "As an organization, we are consistently looking for ways to innovate and grow in the sports sector. Events like Pokatok are great for advancing sports within the region and providing unique opportunities for our community!"

Tickets are expected to go on sale in the fall, and the organization is looking for potential speakers and partners. The festival's name derives from sport of pok-a-tok, which dates back thousands of years as the world’s first team sport played throughout Mesoamerica.

“The City of Houston is a sports town to its core and has been host to some of the greatest events and moments in sports,” says Mayor Sylvester Turner in the release. “Pokatok will help further Houston’s vision of being a destination city for global sporting events and innovations. The business community also supports this venture, and I thank them for their involvement and support. This project is an excellent example of local business leaders joining forces to expand the attractions the City has to offer to both residents and visitors.”

Pokatok will take place in and around the George R. Brown Convention Center. Rendering courtesy of Pokatok

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted